FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311156502> ?p ?o ?g. }

• W4311156502 endingPage "307" @default.
• W4311156502 startingPage "298" @default.
• W4311156502 abstract "Contemporary data on infections after intensive chemotherapy for acute myeloid leukemia (AML) are scarce. Cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone (“CLAG-M”) may result in higher remission rates than standard-dose cytarabine plus anthracycline (“7 + 3”) but may result in more infections. We compared moderate to severe infections occurring up to 90 days after the first induction cycle for AML or other high-grade myeloid neoplasms in patients receiving CLAG-M for newly diagnosed (n = 196) or relapsed/refractory disease (n = 131) or 7 + 3 for newly diagnosed disease (n = 115). For newly diagnosed disease, microbiologically documented infections were more frequent after CLAG-M compared to 7 + 3 (adjusted rate ratio, 1.65 [95% CI, 1.06–2.58]; P = 0.03), with a cumulative incidence of 27.8% and 16.5% by day 90, respectively. Patients receiving CLAG-M for relapsed/refractory disease had the highest cumulative incidence of 50.7%. Bacterial bloodstream infections were the most frequent followed by respiratory tract infections. Among 29 patients (7%) who died, infection was a primary or contributing cause of death in 59%. These data indicate that infections continue to cause substantial morbidity in patients treated for AML, especially those treated for relapsed/refractory disease, and are more common with newer, more myelosuppressive regimens such as CLAG-M. Improved strategies for infection prevention are needed." @default.
• W4311156502 created "2022-12-24" @default.
• W4311156502 creator A5000958441 @default.
• W4311156502 creator A5002048183 @default.
• W4311156502 creator A5007308369 @default.
• W4311156502 creator A5018427160 @default.
• W4311156502 creator A5022499343 @default.
• W4311156502 creator A5025632410 @default.
• W4311156502 creator A5041595049 @default.
• W4311156502 creator A5044399026 @default.
• W4311156502 creator A5057612788 @default.
• W4311156502 creator A5066251957 @default.
• W4311156502 creator A5069050286 @default.
• W4311156502 creator A5069972979 @default.
• W4311156502 creator A5071526115 @default.
• W4311156502 creator A5073013837 @default.
• W4311156502 creator A5086909430 @default.
• W4311156502 creator A5090743307 @default.
• W4311156502 date "2022-12-12" @default.
• W4311156502 modified "2023-10-15" @default.
• W4311156502 title "Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms" @default.
• W4311156502 cites W1569756545 @default.
• W4311156502 cites W1637025955 @default.
• W4311156502 cites W1831954428 @default.
• W4311156502 cites W1968735244 @default.
• W4311156502 cites W1989345554 @default.
• W4311156502 cites W2083336892 @default.
• W4311156502 cites W2086693204 @default.
• W4311156502 cites W2089855381 @default.
• W4311156502 cites W2116363536 @default.
• W4311156502 cites W2116858301 @default.
• W4311156502 cites W2117730870 @default.
• W4311156502 cites W2123859227 @default.
• W4311156502 cites W2144395887 @default.
• W4311156502 cites W2163974548 @default.
• W4311156502 cites W2166528873 @default.
• W4311156502 cites W2327788740 @default.
• W4311156502 cites W2339658711 @default.
• W4311156502 cites W2411727003 @default.
• W4311156502 cites W2557120254 @default.
• W4311156502 cites W2604375031 @default.
• W4311156502 cites W2742285242 @default.
• W4311156502 cites W2753105914 @default.
• W4311156502 cites W2802609999 @default.
• W4311156502 cites W2900431442 @default.
• W4311156502 cites W2912130549 @default.
• W4311156502 cites W2978944417 @default.
• W4311156502 cites W2995432985 @default.
• W4311156502 cites W3000477794 @default.
• W4311156502 cites W3006439519 @default.
• W4311156502 cites W3008185777 @default.
• W4311156502 cites W3020949602 @default.
• W4311156502 cites W3087185289 @default.
• W4311156502 cites W3097629286 @default.
• W4311156502 cites W3108541184 @default.
• W4311156502 cites W3204534487 @default.
• W4311156502 cites W3213327045 @default.
• W4311156502 cites W3214238998 @default.
• W4311156502 doi "https://doi.org/10.1038/s41375-022-01786-9" @default.
• W4311156502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36509892" @default.
• W4311156502 hasPublicationYear "2022" @default.
• W4311156502 type Work @default.
• W4311156502 citedByCount "4" @default.
• W4311156502 countsByYear W43111565022023 @default.
• W4311156502 crossrefType "journal-article" @default.
• W4311156502 hasAuthorship W4311156502A5000958441 @default.
• W4311156502 hasAuthorship W4311156502A5002048183 @default.
• W4311156502 hasAuthorship W4311156502A5007308369 @default.
• W4311156502 hasAuthorship W4311156502A5018427160 @default.
• W4311156502 hasAuthorship W4311156502A5022499343 @default.
• W4311156502 hasAuthorship W4311156502A5025632410 @default.
• W4311156502 hasAuthorship W4311156502A5041595049 @default.
• W4311156502 hasAuthorship W4311156502A5044399026 @default.
• W4311156502 hasAuthorship W4311156502A5057612788 @default.
• W4311156502 hasAuthorship W4311156502A5066251957 @default.
• W4311156502 hasAuthorship W4311156502A5069050286 @default.
• W4311156502 hasAuthorship W4311156502A5069972979 @default.
• W4311156502 hasAuthorship W4311156502A5071526115 @default.
• W4311156502 hasAuthorship W4311156502A5073013837 @default.
• W4311156502 hasAuthorship W4311156502A5086909430 @default.
• W4311156502 hasAuthorship W4311156502A5090743307 @default.
• W4311156502 hasBestOaLocation W43111565021 @default.
• W4311156502 hasConcept C120665830 @default.
• W4311156502 hasConcept C121332964 @default.
• W4311156502 hasConcept C126322002 @default.
• W4311156502 hasConcept C2776694085 @default.
• W4311156502 hasConcept C2777063308 @default.
• W4311156502 hasConcept C2778041864 @default.
• W4311156502 hasConcept C2778729363 @default.
• W4311156502 hasConcept C2779200787 @default.
• W4311156502 hasConcept C2779282312 @default.
• W4311156502 hasConcept C2780923524 @default.
• W4311156502 hasConcept C61511704 @default.
• W4311156502 hasConcept C71924100 @default.
• W4311156502 hasConcept C72563966 @default.
• W4311156502 hasConcept C88879693 @default.
• W4311156502 hasConcept C90924648 @default.
• W4311156502 hasConceptScore W4311156502C120665830 @default.

• next